CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 57 enrolled
Drug / intervention
TrueTeardevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03097614
NCT03097614N/ACompleted

Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye Symptom Relief Assessed During Exposure to a Controlled Adverse Environment (CAE®) Following a 45 Day Period With Application of TrueTear™

Oculeve, Inc.·interventional·Posted Mar 31, 2017·Updated Oct 18, 2018

In Brief

A clinical study evaluating TrueTear for Dry Eye and Dry Eye Syndromes. Completed, enrolled 57 participants across 1 site.

Detailed Summary

This study characterizes acute dry eye symptom control, assessed during exposure to a Controlled Adverse Environment, following use of the TrueTear for 45 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 31, 2017
Enrollment StartMar 31, 2017
Primary CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.3 years ago

Interventions

TrueTeardevice

The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.